LP
BDTX icon

LMR Partners’s Black Diamond Therapeutics BDTX Stock Holding History

LMR Partners’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,349
Closed -$9.31K – 1381
2024
Q4 		$9.31K Buy
+4,349
New +$12.5K ﹤0.01% 1118
2024
Q2 		– Sell
-10,361
Closed -$52.5K – 1112
2024
Q1 		$52.5K Buy
+10,361
New +$41.8K ﹤0.01% 981

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

LMR Partners's BDTX Position: Q1 2025 in Review

LMR Partners sold out of Black Diamond Therapeutics (BDTX) in Q1 2025, closing a stake of 4,349 shares — an estimated $9.31K sold.

LMR Partners first reported a position in BDTX in Q1 2024 and held it in 2 quarters. The position peaked at $52.5K in Q1 2024. 84 funds tracked by Wall St. Rank hold BDTX as of Q1 2025.

  • LMR Partners reported no remaining Black Diamond Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 4,349 Black Diamond Therapeutics shares in Q1 2025, an estimated $9.31K.
  • LMR Partners first reported a position in Black Diamond Therapeutics in Q1 2024 and held it in 2 quarters.
  • LMR Partners's Black Diamond Therapeutics position peaked at $52.5K in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.